In a mouse model of MS, ultrahigh-field MRI detected lesions not visible with conventional MRI. The technique also detected signs of spinal cord ischemia in human patients with MS.

MS prescribing depends on balancing benefit against hard-to-assess risk. At the recent World Congress of Neurology in Vienna, two experts in MS debated whether physicians rate the risk of disabling MS less than the risk of effective treatment. The debate centered on how clinicians and patients perceive risk and how decision-making must be done collaboratively.